Statement: There are four types of adverse events in the primary trial, for which no occurences are recorded.
Primary_evidence: Adverse Events 1:   Total: 47/254 (18.50%)   Anaemia 1/254 (0.39%)   Febrile neutropenia 1/254 (0.39%)   Lymphadenopathy 1/254 (0.39%)   Acute myocardial infarction 1/254 (0.39%)   Angina pectoris 0/254 (0.00%)   Angina unstable 0/254 (0.00%)   Bundle branch block left 0/254 (0.00%)   Cardiac failure 4/254 (1.57%)   Coronary artery disease 0/254 (0.00%)   Coronary artery stenosis 1/254 (0.39%) Adverse Events 2:   Total: 56/269 (20.82%)   Anaemia 1/269 (0.37%)   Febrile neutropenia 0/269 (0.00%)   Lymphadenopathy 0/269 (0.00%)   Acute myocardial infarction 0/269 (0.00%)   Angina pectoris 3/269 (1.12%)   Angina unstable 1/269 (0.37%)   Bundle branch block left 1/269 (0.37%)   Cardiac failure 1/269 (0.37%)   Coronary artery disease 1/269 (0.37%)   Coronary artery stenosis 0/269 (0.00%)